The Evolving Role of an Anti-CD38 Antibody in R/R Myeloma Management

 

ASH 2022 Conference Coverage
Avatar

IKEMA Subgroup Analysis: Isatuximab + Carfilzomib & Dexamethasone in Patients With Early vs. Late Relapsed MM

By ASH 2022 Conference Coverage FEATURING Thomas Martin
By ASH 2022 Conference Coverage FEATURING Thomas Martin
1,466 views
January 20, 2023
0 Comments
Login to view comments. Click here to Login
The Evolving Role of an Anti-CD38 Antibody in R/R Myeloma Management
15:36
Memorial Sloan Kettering Cancer Center

Key Myeloma & MGUS Updates From ASH

Feat. S. Mailankody
33:46
MyCancerHaven

Triple-Class Refractory MM Treatment Updates

Feat. R. Vij, S. Bal
17:52
Indy Hematology Review

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Feat. K. Anderson
35:37
University of Colorado Division of Hematology

2024 Updates on Multiple Myeloma Treatment

Feat. D. Sherbenou
07:37
ASH 2022 Conference Coverage

IKEMA Subgroup Analysis: Isatuximab + Carfilzomib & Dexamethason…

Feat. T. Martin
07:27
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Dual Targeting of SLAMF-7 and CD38 - A Ph2 …

Feat. B. Dhakal
10:25
Srinivas Devarakonda

Choosing Appropriate Patients for Treatment With Monoclonal Antibody…

09:00
Insights from 2023 IMS Annual Meeting

IMS 2023 Insights: "Time to Tailor? Treatment Selection at Firs…

Feat. M. Delforge
21:17
5th SOHO Italy Annual Conference

Health-Related Quality of Life in R/R MM

Feat. M. Delforge
15:01
Patrick Hagen

Treating High-Risk Pts With Early-Relapsed MM

12:35
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Treatment Options for Patients With Myelo…

Feat. C. Cerchione
20:26
MyCancerHaven

Experts Discuss the Management of Multiple Myeloma at First Relapse

Feat. R. Vij, B. Lipe
47:07
Louisville Hematology Highlights

Updates on the Progress in Multiple Myeloma

Feat. D. Reece